Analysts Set Perrigo Company plc (NYSE:PRGO) Price Target at $20.33

Perrigo Company plc (NYSE:PRGO) has earned an average rating of “Reduce” from the five research firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $20.3333.

PRGO has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Zacks Research lowered Perrigo from a “hold” rating to a “strong sell” rating in a research report on Friday, November 7th. Jefferies Financial Group cut their target price on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. Wall Street Zen cut shares of Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Canaccord Genuity Group dropped their price objective on Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, November 6th.

Perrigo Stock Down 0.8%

Shares of NYSE PRGO opened at $15.05 on Friday. The stock has a market cap of $2.07 billion, a PE ratio of -39.60 and a beta of 0.40. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81. Perrigo has a 12-month low of $12.17 and a 12-month high of $30.93. The company has a 50-day moving average of $13.76 and a 200 day moving average of $19.99.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Perrigo had a positive return on equity of 9.16% and a negative net margin of 1.21%.The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the business earned $0.81 earnings per share. The business’s revenue was down 4.1% compared to the same quarter last year. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. As a group, sell-side analysts predict that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th were paid a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 7.7%. The ex-dividend date was Friday, November 28th. Perrigo’s dividend payout ratio is currently -305.26%.

Insider Activity

In other news, Director Geoffrey M. Parker bought 7,500 shares of Perrigo stock in a transaction dated Wednesday, November 12th. The stock was acquired at an average cost of $14.18 per share, with a total value of $106,350.00. Following the acquisition, the director owned 17,375 shares of the company’s stock, valued at approximately $246,377.50. This trade represents a 75.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its holdings in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the period. Huntington National Bank raised its position in Perrigo by 237.8% in the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after purchasing an additional 742 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Perrigo by 54.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after purchasing an additional 424 shares during the last quarter. Hantz Financial Services Inc. increased its stake in Perrigo by 101.0% in the second quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after purchasing an additional 620 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in shares of Perrigo by 89.1% in the third quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock valued at $38,000 after buying an additional 838 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Key Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Analysts set a $20.33 price target for PRGO, implying upside from current trading levels and acting as a potential support for the stock if sentiment stabilizes. Analysts Set Perrigo Price Target
• Neutral Sentiment: Multiple firms issued reminders about the January 16, 2026 lead‑plaintiff deadline for a class action covering purchases between Feb. 27, 2023 and Nov. 4, 2025 — procedural notices that notify investors of rights but do not by themselves change Perrigo’s fundamentals. PR Newswire Deadline Notice
• Negative Sentiment: A flurry of class‑action filings and firm solicitations (Rosen Law, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Schall Law, Bragar Eagel & Squire, The Gross Law Firm, etc.) allege securities‑fraud violations and seek lead plaintiffs — the proliferation of competing claims and publicity increases legal uncertainty, potential defense costs, and investor concern, which likely pressured PRGO shares today. Business Wire Rosen Notice GlobeNewswire Bronstein Notice GlobeNewswire Levi & Korsinsky

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.